

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Hong Kong Life Sciences and Technologies Group Limited

香港生命科學技術集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 8085)

**APPOINTMENT OF EXECUTIVE DIRECTOR;
POSTPONEMENT OF ANNUAL GENERAL MEETING
AND
CHANGE OF CLOSURE OF REGISTER OF MEMBERS**

APPOINTMENT OF EXECUTIVE DIRECTOR

The board (the “**Board**”) of directors (the “**Directors**”) of Hong Kong Life Sciences and Technologies Group Limited (the “**Company**”) is pleased to announce that Dr. Sun Yu (“**Dr. Sun**”) has been appointed as an executive Director with effect from 7 August 2017.

Dr. Sun, aged 45, has over 10 years of experience in management and investment. He is a director of 北京西格碼列頓信息技術有限公司 (Beijing Xigmar Information Technology Limited*) since May 2017 and was a partner of 四川天府瑞領股權投資基金管理有限公司 (Sichuan Tianfu Realeader Investment Fund Management Corporation Ltd. *) from April 2016 to April 2017. Dr. Sun holds a Doctor of Philosophy in Systems Design Engineering from University of Waterloo, Canada and a Bachelor Degree in Computer Application from 哈爾濱工業大學 (Harbin Institute of Technology*, China).

Dr. Sun has not entered into any service agreement nor has any specified or proposed length of service with the Company in respect of his appointment but he is subject to retirement by rotation and re-election at least once every three years at the annual general meeting of the Company in accordance with the articles of association of the Company (the “**Article**”). Pursuant to the Article, Dr. Sun will hold office until the annual general meeting of the Company dated 15 September 2017 and shall be eligible for re-election.

* *For identification only*

Dr. Sun will be entitled to a director's fee of HK\$504,000 per annum, which has been recommended by the remuneration committee of the Company and determined by the Board with reference to his duties and responsibilities with the Company and its subsidiaries (the "**Group**") and the market benchmark.

Save as disclosed above, at the date of this announcement, Dr. Sun did not (i) hold any other position with the Group; (ii) hold any directorships held in the last three years in other listed companies; (iii) have other major appointments and professional qualifications; (iv) have any interests or underlying interests in the shares of the Company within the meaning of Part XV of the SFO (Chapter 571 of the Laws of Hong Kong); and (v) have any relationship with any Directors, senior management of the Company, substantial shareholders or controlling shareholders (having the meaning ascribed to it the Rules (the "**GEM Listing Rules**") Governing the Listing of Securities on the Growth Enterprise Market (the "**GEM**") of the Stock Exchange) of the Company.

Save as disclosed herein, there is no other matter that need to be brought to the attention of the shareholders of the Company (the "**Shareholders**") nor other information relating to Dr. Sun is required to be disclosed pursuant to Rule 17.50(2)(h) to (v) of the GEM Listing Rules.

The Board would like to take this opportunity to welcome Dr. Sun to join the Company.

POSTPONEMENT OF ANNUAL GENERAL MEETING

In view of the new appointment of Dr. Sun as an executive Director, the Board decided to postpone the annual general meeting (the "**AGM**") as the Articles provides that any Directors appointed by the Board shall hold office until the next following AGM of the Company and shall then be eligible for re-election at the AGM.

References are made to the circular (the "**Circular**") of the Company and the notice of the AGM of the Company (the "**AGM Notice**"), both dated 11 July 2017. The AGM originally scheduled to be held at on 11:00 a.m. on Friday, 11 August 2017 will be postponed to 11:00 a.m. on Friday, 15 September 2017 (the "**Adjourned AGM**"). The venue of the Adjourned AGM will remain unchanged at 5/F., Euro Trade Centre, 13-14 Connaught Road Central, Hong Kong.

A supplemental circular (the "**Supplemental Circular**") will be sent to the Shareholders with information in respect of the arrangement of the Adjourned AGM and the additional resolution to be proposed at the Adjourned AGM for the re-election of Dr. Sun as an executive Director. Shareholders are advised to read the Supplemental Circular together with the Circular for information relating to the voting arrangement.

CHANGE OF CLOSURE OF REGISTER OF MEMBERS

The register of members of the Company will be closed from 12 September 2017 to 15 September 2017, both days inclusive, during which period no transfer of Shares will be registered. For determining the entitlement of members of the Company to attend and vote at the Adjourned AGM, all share transfer documents accompanied by the relevant share certificates must be lodged with the Company's branch share registrar and transfer office in Hong Kong, Tricor Standard Limited, at Level 22, Hopewell Centre, 183 Queen's Road East, Hong Kong, no later than 4:30 p.m. on 11 September 2017 for registration.

By order of the Board
Hong Kong Life Sciences and Technologies Group Limited
Lu Zhiqiang
Executive Director and Chief Executive Officer

Hong Kong, 7 August 2017

As at the date of this announcement, the Board comprises (i) six executive Directors, namely Mr. David Lin Kao Kun, Mr. Lu Zhiqiang, Mr. Chui Kwong Kau, Mr. Jiang Hongqing, Ms. Li Mei and Dr. Sun Yu; (ii) one non-executive Director, namely Ms. Lam Kuo; and (iii) four independent non-executive Directors, namely Mr. Hung Yat Ming, Mr. Chan Yun Hing, Mr. Gui Qiangfang and Mr. Zhang James Jian Yuan.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the "Latest Company Announcements" page of the GEM website at <http://www.hkgem.com> for a minimum period of seven days from the date of its publication and on the Company's website at <http://www.hklifesciences.com>.